what happened to amlx：Amylyx's (AMLX) ALS Drug Fails Pivotal Study
Amylyx's (AMLX) ALS Drug Fails Pivotal Study
2024年3月11日—SharesofAmylyxPharmaceuticalsAMLXnosedived82.2%onMar8aftermanagementannouncedtoplineresultsfromthephaseIIIPHOENIXstudyevaluatingRelyvrio.。其他文章還包含有：「AmylyxPharmaceuticalsstockdrops80%afterALSdrug...」、「Amylyx'sapprovedALSdrugflunkscrucialtest」、「AmylyxPlummetsasALSDrugFailstoBenefitPatients」、「AmylyxPharmaceuticals」、「AMLXStockCrashesAsPatientsDropOffALSDrug...
查看更多 離開網站
Amylyx Pharmaceuticals stock drops 80% after ALS drug ...
https://www.marketwatch.com
Amylyx Pharmaceuticals shares dropped more than 80% early Friday after the company said its ALS treatment Relyvrio failed a late-stage trial ...
Amylyx's approved ALS drug flunks crucial test
https://www.reuters.com
Amylyx Pharmaceuticals is considering withdrawing its treatment for amyotrophic lateral sclerosis from the market after the drug failed to ...
Amylyx Plummets as ALS Drug Fails to Benefit Patients
https://www.bloomberg.com
Amylyx Pharmaceuticals Inc. plummeted as its drug for amyotrophic lateral sclerosis failed to benefit patients in a trial.
Amylyx Pharmaceuticals
https://finance.yahoo.com
Amylyx acquired the hyperinsulinemic hypoglycaemia GLP1-RA candidate after previous developers Eiger filed for bankruptcy. Clinical Trials Arena • 2 months ago.
AMLX Stock Crashes As Patients Drop Off ALS Drug ...
https://www.investors.com
Amylyx missed Wall Street's expectations on Thursday amid struggles for its amyotrophic lateral sclerosis drug, and AMLX stock crashed.
Amylyx Pharmaceuticals
https://seekingalpha.com
Amylyx faces challenges after a failed drug, but management is optimistic with a strong balance sheet and new opportunities for investors.
Amylyx ALS drug fails crucial study
https://www.biopharmadive.com
A large clinical trial meant to confirm the benefits of a new ALS medication has instead failed, dealing a major blow to the therapy's developer as well as ...
Amylyx Stock Crashes After ALS Treatment Fails In Its ...
https://www.investors.com
Amylyx stock crashed Friday, losing almost all of its value, after the company said its approved ALS treatment, Relyvrio, failed in a pivotal study.
Amylyx Pharma to remove ALS drug from US
https://www.reuters.com
Amylyx Pharmaceuticals (AMLX.O) will withdraw its amyotrophic lateral sclerosis (ALS) drug - its only product in the market - from the US and Canada.